Latest Tranzyme Pharma Stories
Tranzyme Pharma, a biopharmaceutical company engaged in the discovery and clinical development of first-in-class small molecule therapeutics, announced that Dr.
Tranzyme Pharma today announced positive Phase IIb results for its first-in-class, highly potent and selective ghrelin agonist, TZP-101, for the management of postoperative ileus (POI).
Tranzyme Pharma, a leading biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of gastrointestinal (GI) and metabolic disorders, announced today that the Company has received Notices of Allowance from the U.S.
Tranzyme Pharma has reported positive results from a 'thorough QT/QTc' study of its lead product TZP-101, an intravenous gastrointestinal prokinetic agent currently in two Phase IIb trials for the treatment of postoperative ileus and severe gastroparesis.
Tranzyme Pharma announces the successful results from a "Thorough QT/QTc" study of the company's lead product TZP-101, an intravenous gastrointestinal prokinetic agent currently in two Phase IIb trials for the treatment of postoperative ileus (POI) and severe gastroparesis.
Tranzyme Pharma announced today the successful completion of a Phase I, placebo-controlled, single ascending dose study of its orally administered ghrelin agonist, TZP-102. TZP-102 is the second drug candidate from Tranzyme's internal R&D efforts to reach clinical development.
Tranzyme Pharma today announced that Dr. Philippa Charlton has joined the Company as Medical Director, Clinical Development, a newly created position. In this new position, Dr.